Viatris, Inc. (VTRS)

Viatris's stock experienced several events in the past six months. On February 27, 2025, the stock dropped sharply by 15% due to regulatory issues at its Indore, India facility. On May 8, 2025, despite an 11% year-on-year decline in total revenues, the stock soared by nearly 10% due to stable full-year guidance, positive updates on its drug pipeline, and debt reduction efforts. On August 7, 2025, Viatris reported its Q2 2025 financial results and reiterated its financial guidance for 2025. On September 23, 2025, the company received FDA approval for its first generic Iron Sucrose Injection and was removed from the FTSE All-World Index. On October 13, 2025, Viatris announced its participation in upcoming healthcare investor conferences in November 2025. On October 15, 2025, Viatris completed its acquisition of Aculys Pharma. On October 18, 2025, an analyst initiated coverage of Viatris with a 'Buy' rating and a $15 price target. On October 28, 2025, Viatris entered a research collaboration agreement with Locus Biosciences.

There is no explicit information indicating significant demand seasonality across Viatris's broad and diverse portfolio of generic, branded, and biosimilar medicines. The company's wide range of therapeutic areas and global presence suggest that overall demand might be relatively stable, although specific products within its portfolio could be subject to seasonal fluctuations.

Viatris Inc. is a global healthcare company formed in November 2020 through the merger of Mylan N.V. and Pfizer Inc.'s Upjohn division, headquartered in Pittsburgh, Pennsylvania. It operates in the pharmaceutical industry, aiming to provide access to high-quality, affordable medicines globally, bridging the gap between generics and brands. Viatris has a diverse portfolio of branded drugs, generic and complex generic medicines, and biosimilars, addressing various therapeutic areas, including cardiovascular, central nervous system, dermatology, diabetes, eye care, gastroenterology, immunology, oncology, and respiratory conditions. The company focuses on developing complex and novel products, such as insulin analogs, respiratory products, complex sterile products, topicals and transdermals, complex oral solid dosage forms, high potency products, traditional generics, drug/device combinations, and complex injectables.

Viatris operates globally, supplying medicines to approximately 1 billion patients annually across more than 165 countries and territories. The company segments its operations into four key regions: Developed Markets, Greater China, JANZ, and Emerging Markets. Its extensive commercial reach is supported by manufacturing facilities and development centers worldwide.

Viatris's brand reputation has been influenced by both positive recognition and significant challenges in the past year. In September 2023, Viatris was named to TIME's World's Best Companies 2023 list. However, the company's reputation has been negatively impacted by regulatory issues at its Indore, India manufacturing facility, including an FDA warning letter and import alert, leading to investor scrutiny and lawsuits alleging potential securities fraud.

Viatris Inc. has a widely distributed ownership structure, with institutional investors holding approximately 56.17% of the company's stock. Public companies and individual investors hold about 43.59%, and insiders hold 0.24%. Major institutional owners include Vanguard Group Inc, BlackRock, Inc., Price T Rowe Associates Inc /md/, Davis Selected Advisers, State Street Corp, Dimensional Fund Advisors Lp, Geode Capital Management, Llc, Invesco Ltd., Deerfield Management Company, L.P., and Ameriprise Financial Inc.